Supplementary Table 3 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non–Small-Cell Lung Cancer
Develop an EGFR mutation gene expression signature to aid in predicting response and clinical outcome and to identify genes associated with the EGFR-dependent phenotype 17 primary lung adenocarcinomas
1Total number of mutations: EGFR, n = 1627; TP53, n = 2387. 2The number of singlets, doublets and multiplets in EGFR is 1526, 98 and 5, respectively 3The number of singlets, doublets and multiplets in
Mutations (including Missense point mutations/deletion/insertion) frequencies in 45 genes (737 loci) of lung cancer patients at different stagings according to AJCC staging.
